Sign in
Enrolling by invitationNo phase

Studies people with REM sleep behavior disorder to prepare future brain-protection trials

Enrolls people with REM sleep behavior disorder and healthy volunteers, to prepare future trials.

Key facts

Who runs it
Washington University School of Medicine
Where
Atlanta, Boston, Los Angeles, Minneapolis, Portland, Redwood City, Rochester, and St Louis, United StatesSee the 8 sitesAlso in 1 other country, 1 site
Trial code
Registry title
North American Prodromal Synucleinopathy Consortium Stage 2
Status
Enrolling by invitation
People taking part
500 people, planned
Started
12 Aug 2022
Expected to end
1 May 2028
Type of study
Observational, 2 groups
Record updated
13 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with REM sleep behavior disorder (RBD) confirmed by a sleep study, and healthy adults as a control group.

Age
Adults over 18 years.
Sex
All sexes can join.
Disease stage
RBD group: REM sleep behavior disorder confirmed by an overnight sleep study (polysomnogram). Control group: no sign of RBD.

Main reasons for not taking part

  • RBD group: Parkinson's disease, any dementia, or multiple system atrophy (MSA), unless the person took part in NAPS1
  • RBD group: narcolepsy-related RBD, or RBD with a known cause other than an early synucleinopathy
  • Control group: history of acting out dreams, parkinsonism, MSA, dementia or mild cognitive impairment
  • Control group: cannot have a full MRI or a lumbar puncture
  • Both groups: taking part in another clinical trial, unless the study's Executive Committee gives permission

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Polysomnogram-confirmed RBD by ICSD-3 criteria
  • Capable of providing informed consent at time of study enrollment
  • Age > 18 years
  • Ability to provide written consent
  • Age > 18 years
  • Must meet age, sex, and race matching criteria per the Data Management and Statistical core recommendations for the site
  • Must be willing to undergo all testing procedures, including neuroimaging and lumbar puncture
  • Normal capacity to perform complex activities of daily living independently based on informant or physician report

Who cannot take part

  • Diagnosis of PD, dementia of any type, or MSA unless previous participant in NAPS1
  • In the opinion of the investigator, the individual has a clinically significant uncontrolled medical condition that would impede safe completion of the study protocol
  • History of dream enactment behavior to suggest RBD
  • Parkinsonism, MSA, dementia, or mild cognitive impairment
  • Active central nervous system, systemic, psychiatric condition or use of psychoactive medication that would adversely affect cognitive, neuropsychiatric, motor, or autonomic functioning
  • In the opinion of the investigator, the individual has a clinically significant uncontrolled medical condition that would impede safe completion of the study protocol
  • Narcolepsy-associated RBD
  • RBD secondary to any known cause except prodromal synucleinopathy
  • Participation in a clinical trial, except by specific permission by the Executive Committee
  • Contraindications to complete MRI
  • Contraindications to lumbar puncture
  • Participation in a clinical trial, except by specific permission by the Executive Committee

Where in United States

Also in 1 other country, 1 site

  • Emory UniversityAtlanta, United StatesEnrolling by invitation
  • Massachusetts General HospitalBoston, United StatesEnrolling by invitation
  • University of California, Los AngelesLos Angeles, United StatesEnrolling by invitation
  • University of MinnesotaMinneapolis, United StatesEnrolling by invitation
  • Oregon Health Sciences UniversityPortland, United StatesEnrolling by invitation
  • Stanford UniversityRedwood City, United StatesEnrolling by invitation
  • Mayo Clinic - RochesterRochester, United StatesEnrolling by invitation
  • Washington University School of MedicineSt Louis, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

This study will enroll participants with idiopathic REM sleep behavior disorder (RBD) and healthy controls for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.

The 2 groups in the trial

  • RBD group

    Clinical observation involving annual visits to a study site for up to 5 years.

  • control group

    Clinical observation involving annual visits to a study site for up to 5 years.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
North American Prodromal Synucleinopathy Consortium Stage 2
Plain-language title
Studies people with REM sleep behavior disorder to prepare future brain-protection trialsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Publications
Record updated
13 May 2026